金吾财讯 | Labcorp(LH)宣布，已与肿瘤临床试验联盟达成一项全美战略合作。Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌(CRC)患者及其高危亲属的全国性、多中心大型临床试验。据悉，该研究项目由美国国家卫生研究院(NIH)下属的美国国家癌症研究所(NCI)全额资助，由肿瘤临床试验联盟负责主导和实施。其招募网络广泛，涵盖了全美及波多黎各地区的学术医学中心、社区肿瘤医疗系统以及NCI指定的癌症中心。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.